Much of the key epidemiological evidence that long-term exposure to air pollution contributes to increased risk of mortality comes from survival studies of cohorts of individuals.
Introduction
Epidemiological research concerning air pollution and human health has a rich and complex history (Brimblecombe 1987; Lipfert 1994; Davis 2002; Vedal 1997; Pope and Dockery 2006; Brook et al. 2010; Rajagopalan et al 2018) . Elevated pulmonary and cardiovascular morbidity and mortality accompanied historic air pollution episodes in Meuse Valley, Belgium (1930) , Donora, Pennsylvania (1948), and London, England (1952) (Bell 2001) . Subsequent time-series and related studies provided further evidence that episodic or short-term elevations in air pollution at even moderate levels contribute to cardiopulmonary morbidity and mortality (Pope and Dockery 2006; Brook et al. 2010; Rajagopalan et al 2018) . In the 1970s and 1980s, cross-sectional studies of U.S. populations observed that long-term average concentrations of air pollution were associated with increased mortality rates (Lave and Seskin 1977; Evans et al 1984; Ozkaynak and Thurston 1987) . Various quasi-experimental studies have also observed links with pollution and mortality. For example, a difference-in-differences analysis observed that differential reductions in pollution in the U.S. between 1980 and 2000 were associated with differential improvements in life expectancy (Pope et al. 2009 ). A regression-discontinuity race, cigarette smoking, pipe and cigar smoking, exposure to passive smoke, body mass, education, occupational exposure, and alcohol use. Elevated mortality risks were associated with both PM2.5 and SO4. Estimated HRs per 10 µg/m 3 long-term exposure to PM2.5, were 1.07 (95% CI=1.04-1.10) for all-cause mortality and 1.12 (1.07-1.17) for cardiopulmonary mortality.
The Harvard Six-Cities and ACS CPS-II cohort studies were controversial in part because they reported remarkably robust pollution-mortality associations, especially for cardiopulmonary mortality, and because the pollution-mortality associations were much larger than expected based on the short-term associations observed in the daily time-series studies. There were also concerns about validity, analytic methods, data quality and accessibility. In 1997 the original investigators of both studies agreed to provide the cohort and related study data for an intensive reanalysis by an independent research team (Krewski et al. 2000) . This effort was conducted under the oversight of the Health Effects Institute that assured confidentiality of information from study participants and it provided data quality assurance audits, replication and validation of the originally reported results, and sensitivity analyses.
Subsequently there have been multiple extended analyses of the Harvard Six-Cities cohort (Laden et al. 2006; Lepeule et al. 2012 ) and the ACS CPS-II cohort (Pope et al. 2002; Pope et al. 2004; Smith et al. 2009; Krewski et al. 2009; Jerrett et al. 2009; Turner et al. 2011; Pope et al. 2015; Turner et al. 2016 , Thurston et al. 2016b Jerrett et al. 2017 ). These extended analyses include substantially increased mortality follow-up with much larger numbers of deaths and increased statistical power; improved assessment of air pollution exposures from metro-level averages to modeled exposures at geocoded residential addresses; and improved statistical modeling that allows for control of both individual and ecological covariates. For both the Harvard Six-Cities study and the ACS CPS-II study, estimated adjusted HRs across the originally reported results, the independent reanalysis, and the various extended analyses are remarkably consistent (see Figures 1, 2, and 3).
Meta-analytic compilation of expanding cohort studies
There is a large and growing number of studies that have evaluated pollution-mortality associations in other cohorts from various areas around the world. The HRs (and 95% confidence intervals) from these cohorts are also illustrated in Figures 1, 2 , and 3. The cohort studies illustrated in these figures have been complied based on searches of Medline and supplemented with studies included in reviews by Pope and Dockery (2006) , Brook et al. (2010) , Hoek et al. (2013) , Vodonos et al. (2018) , and the Integrated Science Assessment for Particulate Matter (U.S. Environmental Protection Agency, External Review Draft October 2018). Figures 1-3 , there are now many additional cohort studies from the U.S. including a cohort of California Seventh-day Adventists (McDonnell et al. 2000; Chen et al. 2005 ), a cohort of Cystic Fibrosis patients (Goss et al. 2004 ), a cohort of postmenopausal women from the Women's Health Initiative (WHI) (Miller et al. 2007) , multiple cohorts constructed from U.S. Medicare data (Eftim et al 2008; Zeger et al. 2008; Shi et al. 2016; Kioumourtzoglou et al. 2016; Wang et al. 2017a; Di et al. 2017; Eum et al. 2018 ), a cohort of U.S. veterans (Lipfert et al. 2006) , the Nurses' Health Study cohort (Puett et al 2009; Puett et al. 2014; Hart et al. 2015) , the California Teachers cohort Lipsett et al. 2011; Ostro et al. 2015) , (Wang et al. 2016) , and cohorts constructed from National Health Interview Survey data (Pope et al. 2018a; Parker et al. 2018; Pope et al. 2019 ).
As is illustrated in

Studies from Canada include studies of cohorts based on the Canadian Census Health and
Environment Cohort (Crouse et al. 20012; Crouse et al. 2015; Weichenthal et al. 2016; Pinault et al. 2017; Pinault et al. 2018; Cakmak et al. 2018 ), a Breast Screening cohort (Villeneuve et al. 2015) , a Canadian Community Health cohort , and a cohort of survivors of myocardial infarction (MI) (Chen et al. 2016) . Studies from Europe include cohorts from the Netherlands (Beelen et al. 2008; Fischer et al. 2015; Downward et al. 2018) , France (Filleul et al. 2005; Bentayeb et al. 2015) , Germany (Gehring et al. 2006 ), England (Carey et al. 2013; Dehbi et al. 2017) , Italy (Cesaroni et al. 2013) , Spain (Keijzer et al. 2017 ), Denmark (Hvidtfeldt et al. 2019) , and a coordinated pooled analysis of up to 22 European cohorts (Beelen et al. 2014a; Beelen et al. 2014b; Raaschou-Nielsen et al. 2013; Kimakopoulou et al. 2014) . Studies from Asia include studies of cohorts from Japan (Ueda et al. 2012; Katanoda et al. 2011) and Iran (Yarahmadi et al. 2018) as well as Chinese cohorts from Hong Kong (Wong et al. 2015; Wong et al. 2016 ), Taiwan (Tseng et al. 2015 , and mainland China (Cao et al. 2011; Yin et al. 2017; Li et al 2018) .
Comparisons of the estimated HRs presented in Figures 1-3 provide evidence of adverse
PM2.5-associations with all-cause, cardiopulmonary, and lung cancer mortality. Based on studies reported in Figures 1-3, meta analytic estimates were estimated using Comprehensive Meta Analysis (Version 3.3.070; https://www.meta-analysis.com/). In an effort to be all-inclusive, the meta estimates were calculated for all reported studies. However, to avoid the use of multiple studies of the same or similar cohorts, and to exclude less representative, specialty cohorts (such as Cystic Fibrosis, MI survivors, or TB cohorts) meta estimates were also calculated for only selected studies. The specific selected studies are indicated with black diamond symbols with the size of the diamond proportional to the relative weight in the random effect estimate using selected studies. The selected studies generally included only the study with the largest and longest follow-up for each cohort or similar cohorts. Figures 1-3 suggest that there is heterogeneity in estimates across different cohorts and across different analyses of the same or similar cohorts. Figure 5 provides a plot of the distribution of HRs for all-cause mortality (greater than or less than 1 and statistically significant [p ≤ 0.05] versus not) for all studies and for selected studies. Most, but not all, of the studies observed statistically significant adverse PM2.5-mortality associations. Fixed effect meta-analysis provided further evidence of between study heterogeneity (I 2 > 90; P < 0.001 for all and selected studies of all cause mortality). Given this observed heterogeneity and the likelihood of real differences in effects across cohorts, fixedeffect meta estimates would not be appropriate. Therefore, random-effects meta estimates, that estimate the mean of the distribution of effects, were calculated.
Visual comparisons of the estimated HRs presented in
Based on the random-effects meta estimates using the selected studies, the estimated HRs per 10 µg/m 3 long-term exposure to PM2.5, is 1.08 (95% CI=1.06-1.10) for all-cause mortality, 1.11 (1.08-1.14) for cardiopulmonary mortality, and 1.13 (1.07-1.20) for lung cancer mortality.
Similar HR estimates were obtained using all studies. For all-cause and lung cancer mortality the meta estimates are similar for North American, European, and Asian studies. For cardiopulmonary mortality, the meta estimated HR is larger for North America. These results are comparable to previously reported estimates (Hoek et al. 2013; Vodonos et al. 2018 ). To explore for publication or selection bias, funnel plots of standard errors plotted over log hazard ratios for all-cause mortality are presented in Figure 4 . The funnel plot on the left includes all studies except the China TB study (which is clearly a unique outlier cohort and falls outside of the scale of Figure 4 ). The funnel plot on the right includes all selected studies (as indicated with black diamonds in Figure 1 ). Although funnel plots are not definitive, the plots presented in Figure 4 do not provide substantive evidence of publication or selection bias.
Key Controversies
There have been various controversies regarding the results and use of cohort studies of long-term exposure to PM2.5 and mortality risk. Some of these controversies and concerns have been at least partially resolved. The initial controversies regarding the need for independent reanalyzes and replication of early studies has been reasonably well addressed. With regards to the original Six-Cities and ACS CPS-II cohort studies, intensive independent reanalysis as well as substantial extended analyses have been conducted. Furthermore, although it is not generally possible to fully replicate original epidemiological studies, PM2.5-mortality associations have been observed in many different cohorts and by many different research teams. Although there are limitations to using meta-analytic approaches to summarize this large and growing literature, random-effects meta estimates of the mean of the distribution of effects indicate highly statistically significant adverse PM2.5-mortality associations for all-cause mortality, cardiopulmonary mortality, and lung-cancer mortality.
Another controversy regarding cohort studies of mortality and air pollution is the assertion that they are "Secret Science" because they use private and confidential health and personal data with ethical and legal restrictions on the release of these data. Data collected for cohort studies often involve confidentiality agreements with research participants. Proposed legislation (Michaels and Burke 2017) and a proposed U.S. Environmental Protection Agency rule (Cornwall 2018) would disallow the EPA from using scientific research that is not public data. It is unclear how this controversy can be fully resolved, because of continued counter demands to protect private health and personal data. However, recently there have been cohort studies of air pollution and mortality that have used public data. Di et al (2017) constructed a massive open cohort of over 60 million persons with nearly 0.5 billion person-years of follow-up using the U.S. Medicare data from the Centers for Medicare and Medicaid Services. The estimated HR per 10 µg/m 3 long-term exposure to PM2.5, from this study was 1.073 (95% CI=1.071-1.075) for all-cause mortality-similar to the meta-estimate from the combined studies (see Figure 1 ). Parker et al (2018) and Pope et al (2019) estimated PM2.5-mortality HRs from constructed cohorts using public data from National Health Interview Surveys, linked to the National Death Index. The estimated HRs per 10 µg/m 3 long-term exposure to PM2.5, from these studies for all-cause mortality were 1.08 (95% CI=1.01-1.16) and 1.12 (95% CI=1.09-1.15) respectively-again comparable to the meta-estimate from the combined studies (See Figures 1-2) . Similarly, the studies of the Canadian Census Health and Environment Cohort (Crouse et al. 2012; Crouse et al. 2015; Weichenthal et al. 2016; Crouse et al. 2016; Pinault et al. 2017; Pinault et al. 2018; Cakmak et al. 2018 ) and the Canadian Community Health Cohort ) use public data. There is little evidence of substantially different estimated PM2.5mortality HRs using cohorts constructed from public data. The random-effects meta estimate using only selected studies using these public cohorts (Di et al. 2017; Pope et al. 2019; Crouse et al. 2015; Pinault et al. 2016) , resulted in a somewhat larger HR per 10 µg/m 3 long-term exposure to PM2.5, of 1.10 (95% CI=1.08-1.13) for all-cause mortality. Even with public data sets, however, there is typically limited and controlled access to underlying data such as sex, race, age, birth and death dates, linked with specific geographic information regarding place of residence (which is required for linkage with air pollution data), and that may allow for personal identification.
Another controversial basic limitation of these cohort studies is their inability to definitively establish causal effects or provide specific biological mechanisms or even plausibility. These studies, however, provide evidence of consistency and coherency of PM2.5mortality associations and they can suggest epidemiological evidence of general pathophysiological pathways of disease (Pope et al. 2004) . The cohort studies of long-term air Additional controversy regarding the PM2.5-mortality cohort studies relates to their use in developing risk functions to estimate burden of disease attributable to air pollution. A key controversy pertains to the shape of the PM2.5-mortality exposure-response relationships.
Estimators that integrate risk estimates from air pollution, second-hand cigarette smoke (SHS) and active smoking have been developed. For example, Figure 6 presents a stylized illustration of an integrated exposure-response (IER) relationship between cardiopulmonary disease mortality and long-term exposure to PM2.5 from multiple sources. The estimates presented using gray scale symbols are estimates from exposures to cigarette smoke from active smoking and from second-hand smoke as documented elsewhere (Pope et al. 2011 (Pope et al. , 2018b . The colored symbols are estimates from exposures to air pollution from selected studies from Canada (yellow, Crouse et al. 2015; Pinault et al. 2016) , the U.S. (blue, Lepeule et al. 2012; Pope et al. 2015 Pope et al. , 2019 , and China (green, Yin et al. 2017; Li et al. 2018 [estimate for all-cause mortality]), and the random effects meta estimate from the selected studies from the present meta-analysis (red, Figure 2 ). The adjusted relative risks are scaled and presented per approximate average PM2.5 concentrations in each of the studies. The maroon curve illustrates an IER function with the mathematical form used in the global burden of disease estimates Cohen et al. 2017) As is illustrated in Figure 6 , the integrated response function across the full range of exposures, including active smoking is not linear but levels off at high levels of exposures.
However, the IER function does not allow for differential toxicity across different sources of PM2.5 and does not fit the studies of air pollution well. The elevated mortality risks from studies with very low average exposures (Canadian studies) tend to be lower than the IER estimates and the elevated mortality risks from studies with high exposures (China) tend to be higher than the IER estimates. In fact, recent estimates of the shape of the PM2.5-mortalty exposure-response relationship, using only estimates from cohort studies of ambient PM2.5, suggest an exposureresponse relationship that does not flatten out as much at high exposures-resulting in much higher global estimates of pollution-related mortality (Burnett et al. 2018; Vodonos et al. 2018) .
Although the HRs per 10 µg/m 3 long-term exposure to PM2.5, are similar in both Canadian and Chinese cohorts (see Figures 1 and 2) , Figure 6 illustrates that the HRs per average exposure are much higher in China than in Canada.
Conclusions
Much has changed in the last 25+ years regarding evidence of long-term pollution exposure contributing to mortality risk. Certainly not all of the controversies and uncertainties have been fully resolved. However, independent reanalysis and substantial extended analysis of the original cohort studies have been conducted. There are now many additional studies using a wide variety of cohorts, including cohorts constructed from public data, that have been reported.
Unsurprisingly, there is considerable heterogeneity in the PM2.5-mortality associations that are estimated across, and even within, different cohorts. This heterogeneity needs to be explored and better understood. There also remains a need for studies from understudied and often highly polluted areas of the world. However, meta-analytic estimates of the mean of the distribution of PM2.5-mortality associations that are currently available, provide evidence of highly statistically significant adverse PM2.5 associations with all-cause, cardiopulmonary, and lung cancer mortality.
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